AdipoGen Life Sciences

Fc (LALA-PG)-KIH (human) IgG1 Control (rec.)

CHF 340.00
In stock
AG-35B-0018-C05050 µgCHF 340.00
More Information
Product Details
Synonyms Fc (LALA-PG) Knobs-into-Holes (human) IgG1; Immunoglobulin 1 Fragment Constant
Product Type Protein
Source/Host HEK 293 cells. Produced using animal component-free medium.

Fc (LALA-PG) (human) IgG1 (Knobs-into-Holes Technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996))

Crossreactivity Human

Fc (LALA-PG)-KIH (human) does not bind to FcRs.

MW ~28kDa (SDS-PAGE)
Purity ≥95% (SDS-PAGE)
Endotoxin Content <0.01EU/μg purified protein (LAL test).
Concentration After reconstitution: 1mg/ml
Reconstitution Reconstitute with 50µl endotoxin-free water.
Accession Number P01857
Formulation Lyophilized. Contains PBS.
Other Product Data

Uniprot: P01857

Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice After reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
PBS containing at least 0.1% BSA should be used for further dilutions.
Use/Stability Stable for at least 6 months after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF

Negative control in experiments with recombinant proteins fused to human IgG1 Fc (LALA-PG)-KIH (Knobs-into-Holes) (e.g. Prod. No. AG-40B-0248). This protein is not an appropriate negative control for other standard Fc protein constructs.

The protein Fc (LALA-PG)-KIH (human) IgG1 Control (rec.) is produced by using two different vectors, one encoding for the Fc (LALA-PG) Knobs sequence with a small linker (synthesizing a protein of 29kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization and for secretion of the final protein Fc (LALA-PG)-KIH (human) IgG1 Control (rec.). The LALA-PG mutations inhibit binding to FcγRs and C1q while FcRn binding and Fc stability remain unaffected.

InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.